Search

Aim: The aim of this study is to shed light on sarcoidosis from a rheumatology perspective and to provide a better understanding of sarcoidosis from the perspective of a rheumatologist. Materials and Methods: The files of patients who applied to the rheumatology outpatient clinic with joint complaints between 2020 and 2023 and were diagnosed with sarcoidosis during follow-up or who were already diagnosed with sarcoidosis and had joint complaints during the course of the disease, were retrospectively examined. Results: Joint involvement was observed in all patients (100%). When patients were grouped according to the joints involved, it was found that 17 patients had ankle involvement (60.7%), six patients had metacarpophalangeal joint involvement (21.4%), four (14.2%) patients had wrist involvement, and three (10.7%) patients had knee involvement. Shoulder involvement was detected in one (3.5%) patient. Conclusion: Although sarcoidosis seems to primarily concern chest diseases, from the perspective of rheumatology, it is a very confusing and surprising disease with its heterogeneous nature and joint involvement. It is one of the diseases that should be kept in mind and further studied in rheumatology practice.

World Health Organization declared coronavirus disease-19 (COVID-19) as pandemic since 11 March 2020. Herein, new human coronavirus, SARS-CoV2 is the etiologic agent of the disease. Also, it has been a global health problem since it was detected in Chinese province of Wuhan at December 2019. COVID-19 has several different clinical variations from mild disease to acute respiratory distress syndrome. For the treatment of the disease, several remedies have been administered. Even though, anecdotal data showed somewhat effectiveness of those drugs for the treatment of the disease, there has been no accurate scientific knowledge proofing these. Therefore, main purpose of this review was discussing how the physicians arrange the therapies of the rheumatologic diseases during COVID-19, especially while patients are under immunosuppressive drugs. Also, we summarized the current data about the effectiveness of immunosuppressive drugs on COVID-19.